Galapagos NV Stock News

Mechelen, België; 18 januari 2022; 22.01 CET; Galapagos NV (Euronext & Nasdaq: GLPG) maakt vandaag bekend dat het Medicines and Healthcare products Regulatory Agency (MHRA) de handelsvergunning heef

In this article we will take a look at whether hedge funds think Galapagos NV (NASDAQ:GLPG) is a good investment right now.

Biopharma weakened sharply in 2021, driven by the underperformance in SMIDs, a group of analysts from Morgan Stanley laments, noting a "show me" attitude among investors for next year

Mechelen, Belgium; 6 January 2022, 15.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 40 th A nnual J.P. Morgan Healthcare Conference on January 10-13 , 20 22.

Related Stocks: BIIB , IKNA , ABBV , GLPG , SIBN , LUNG , ADGI , ZBH , HCA , ERAS , SGEN , CTKB , PRLD , NTRA , ANTM , AFIB , ABCL , DCPH , AUPH , ASND , TRIL , ARCT , ALXN , ALEC ,

Parametric Portfolio Associates LLC trimmed its holdings in shares of Galapagos NV (NASDAQ:GLPG) by 32.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,510 shares of the biotechnology companys stock after selling 9,289 shares during the quarter. Parametric Portfolio Associates LLCs holdings in []

Equities analysts predict that Galapagos NV (NASDAQ:GLPG) will report earnings of ($1.25) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Galapagos earnings, with the highest EPS estimate coming in at ($0.84) and the lowest estimate coming in at ($1.90). The company is scheduled to report its next earnings []

Analysts predict that Galapagos NV (NASDAQ:GLPG) will report $115.36 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Galapagos earnings, with the highest sales estimate coming in at $172.72 million and the lowest estimate coming in at $58.00 million. The company is scheduled to issue its []

Galapagos is in the midst of a transformation process that is expected to result in a completely different company by 2023. Galapagos has over $5.5 billion in cash, an approved drug and a broad pipeli

Galapagos NV (NASDAQ:GLPG) reached a new 52-week low on Tuesday . The stock traded as low as $47.96 and last traded at $47.96, with a volume of 3144 shares. The stock had previously closed at $49.30. GLPG has been the topic of several research analyst reports. Royal Bank of Canada lifted their price objective on []

Mechelen, Belgium; 22 November 2021, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737

Mechelen, Belgium; 22 November 2021 , 22. 01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD).

Related Stocks: AMRN , KYMR , LXRX , CRNX , RAIN , VSTM , GLPG , AADI , TYRA , PNT , ALPN , ELEV , MRUS , RACA , FBRX , IMVT , CNTA ,

Related Stocks: CI , CAH , UHS , HLF , UTHR , GLPG , MRK , RCOR , GILD , LPTX , PTGX , HRC , AMGN , AFMD , CHRS , SYNH , CHAQ.U ,

Related Stocks: DRNA , RGNX , ARWR , AMYT , ARVN , NGM , HARP , GLPG ,